MedCost Clear Cost calculator

Data / Findings

Wegovy goes from 3% to 100% of Medicare Part D plans in 2027

Published Nov 15, 2026 · version 2026-11-15 · data: CMS's Part D formulary files for 2026 (published Sep 23, 2026) and 2027 (published Oct 15, 2026).

Finding

In CMS's Medicare Part D formulary files, 175 of the 5,496 Part D plans for 2026 (3.2%) list Wegovy, all of them Medicare Advantage plans with drug coverage and none of the 367 standalone drug plans. For 2027, all 5,492 plans list it: 323 of 323 standalone drug plans and 5,169 of 5,169 Medicare Advantage plans with drug coverage. In both years every plan that lists Wegovy requires prior authorization.12

Source: CMS (data.cms.gov), Monthly Prescription Drug Plan Formulary files · our archived copies of Nov 15, 2026 · recounted when this page was built

Why: Medicare negotiated a price for semaglutide

Semaglutide, sold as Ozempic, Rybelsus and Wegovy, is one of the drugs in Medicare's drug price negotiation; CMS names it as the negotiated drug with the highest Part D gross costs in 2024: $15,161,908,000, for 2,282,000 people with Part D who used it.34 From January 1, 2027, its negotiated price is $274 for a 30-day supply, against a $959 list price in 2024 (71% lower); for a box of four Wegovy 2.4 mg pens (NDC 00169-4524-14) CMS gives $385.63.456 CMS's fact sheet on those prices says:

“As required by law, Medicare prescription drug plans, including standalone Part D plans and Medicare Advantage-prescription drug plans, must include in their formularies the selected drugs for which CMS and the participating drug company have agreed to a negotiated price.”
CMS: Medicare Drug Price Negotiation Program, Negotiated Prices for Initial Price Applicability Year 2027 (fact sheet) · as of Oct 23, 2026

What it does not mean

The data

CMS formulary files 2026_20260916.zip and 2027_20261008.zip (our archived copies of Nov 15, 2026). Counts of plans, not people. Download CSV.
Plan year · WegovyPlans that list itShareStandalone drug plansMedicare Advantage with drugsPrior auth.Step therapy
2026 · any form175 of 5,4963.2%0 of 367175 of 5,1291750
2026 · injection175 of 5,4963.2%0 of 367175 of 5,1291750
2026 · tablet (pill)49 of 5,4960.9%0 of 36749 of 5,129490
2027 · any form5,492 of 5,492100%323 of 3235,169 of 5,1695,4920
2027 · injection5,492 of 5,492100%323 of 3235,169 of 5,1695,4920
2027 · tablet (pill)5,492 of 5,492100%323 of 3235,169 of 5,1695,4920

The same files, for comparison:

Drug2026 plans that list it2027 plans that list it
Wegovy3.2%
175 of 5,496
100%
5,492 of 5,492
Ozempic (semaglutide, same negotiated drug)99.1%
5,445 of 5,496
100%
5,492 of 5,492
Zepbound (tirzepatide)0.5%
26 of 5,496
0.1%
7 of 5,492
Mounjaro (tirzepatide)97.2%
5,343 of 5,496
97.0%
5,327 of 5,492

Method

  1. Data: CMS's Monthly Prescription Drug Plan Formulary and Pharmacy Network Information on data.cms.gov. 2026 plans: 2026_20260916.zip, published Sep 23, 2026; 2027 plans: 2027_20261008.zip, published Oct 15, 2026.12 We use the plan information, basic drugs formulary and geographic locator files in each.
  2. A plan is a contract-plan-segment in the plan file, standalone drug plans (PDP) and Medicare Advantage plans with drug coverage (MA-PD, including special needs plans); plans CMS marks as suppressed are left out (22 for 2026, 3 for 2027). Each plan has one formulary: 328 formularies for 2026, 286 for 2027.
  3. A plan lists Wegovy when its formulary has at least one RxNorm code (RxCUI) for a Wegovy injection or tablet. Codes come from NLM's RxNorm (RxNav), and every formulary line whose NDC belongs to semaglutide, tirzepatide, liraglutide or orforglipron is checked against FDA's NDC Directory: the RxCUI must be in our map and RxNorm's brand must equal the NDC Directory's brand, or the count is not published. Prior authorization and step therapy count when at least one listed form carries the flag; the tier is the lowest one the plan gives the drug.
  4. Our copies: each full CMS download (about 2.3 GB) is kept on our U.S. archive server with its SHA-256 (2026: 51d0d4177f00458e…; 2027: 5f3bbe4e9ca29bce…), and the files used are pinned by a manifest. Every time the site is built, the plans are recounted from those pinned files and the build stops if any number above differs from the published figures.
  5. Not included: how many people are in each plan (the files have no enrollment), what a plan charges you, and anything after the 2027 file named above.

How to cite

MedCost Clear, "Wegovy goes from 3% to 100% of Medicare Part D plans in 2027", version 2026-11-15, https://medcostclear.com/data/findings/wegovy-medicare-part-d-2027/

Free to reuse under CC BY 4.0 with credit to MedCost Clear and a link to this page; the license covers our counts. The CMS files and the Federal Register text are U.S. government works.

This page stays as published

A finding is dated: its numbers describe the CMS files named above and do not change when CMS publishes newer monthly files. The current counts, by state, are on Does Medicare cover Wegovy? and in the Medicare Part D GLP-1 Formulary Coverage by State. If we find a mistake, we fix it here and log it on the corrections page. Questions: [email protected].

Which drug, which dose, and whether to start, stop or switch are medical decisions. Ask your doctor or pharmacist.

Official sources for this page (22)
  1. “For example, for the selected drug with the highest total gross covered prescription drug costs under Part D in 2024, Ozempic; Rybelsus; Wegovy, the MFP applied across three commonly used dosage forms and strengths will be:”
  2. “Ozempic; Rybelsus; Wegovy Novo Nordisk Inc. Type 2 diabetes; Type 2 diabetes and cardiovascular disease; Cardiovascular disease and obesity/ overweight $274 $959 71% $15,161,908,000 2,282,000”
  3. “00169-4524-14 2.4 mg /0.75 mL Pen, 4 Pens (Wegovy) $385.63”
  4. “These negotiated prices will become effective on January 1, 2027.”
  5. “Section 11001(b) of the IRA added section 1860D-4(b)(3)(I)(i) of the Act to require that for 2026 and each subsequent year, Part D plans include each covered Part D drug that is a selected drug under section 1192 of the Act on Part D formularies if an MFP is in effect for that drug with respect to that year.”
  6. “For 2026, 2027, and 2028, we have implemented this requirement through guidance.”
  7. “(vii) Except as specified in paragraph (b)(2)(viii) of this section, for 2026 and each subsequent year, include each Part D drug that is a selected drug under section 1192 of the Act for which a maximum fair price (as defined in section 1191(c)(3) of the Act) is in effect with respect to the year.”
  8. “Applicability date: These regulations are applicable to the Negotiation Program beginning with respect to initial price applicability year 2029 and to Part D Program coverage beginning January 1, 2029.”
  9. “CMS will use its comprehensive formulary review process for Medicare prescription drug plans to assess any practices that may undermine access to selected drugs for people with Medicare.”
  10. “If a provider submits a prior authorization request to a Part D plan sponsor for a GLP-1 product that is excluded from coverage under Medicare Part D (agents when used for weight loss) but may be eligible for coverage under the Medicare GLP-1 Bridge, CMS strongly encourages the Part D plan sponsor to assist with directing the claim to the Medicare GLP-1 Bridge for review.”
  11. “to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight.”
  12. “for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in adults.”
  13. “For example, beneficiaries prescribed Zepbound® for the treatment of moderate to severe obstructive sleep apnea in adults with obesity or Wegovy® to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight should continue to receive coverage through Medicare Part D.”
  14. “Additionally, beneficiaries diagnosed with a condition that is currently eligible for coverage under Part D, such as moderate to severe obstructive sleep apnea (OSA), noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced liver scarring (fibrosis), or type 2 diabetes, are not eligible for the Medicare GLP-1 Bridge.”
  15. “At this time, we are not imposing tier placement, utilization management, or other special formulary requirements for selected drugs.”
  16. “we believe our current approach provides Part D plan sponsors with the flexibility to continue to manage costs through utilization management in a clinically appropriate manner, while allowing us to monitor practices that may undermine beneficiary access to selected drugs and potentially inform new requirements for future contract years.”
  17. “Prior authorization is approval based on a plan's specific requirements that you and/or your prescriber must get from a plan for certain drugs before your plan will cover them.”
    Medicare.gov: Drug plan rules · as of Nov 15, 2026
  18. “A participating drug company with a selected drug is required to ensure the negotiated price is made available to eligible individuals and to the pharmacies, mail-order services, and other entities that dispense the selected drug with respect to such individuals.”
  19. “You’ll pay a $50 copayment to the pharmacy for a one-month supply (either 28 or 30 days, depending on drug).”
    Medicare.gov: Weight loss drugs · as of Nov 5, 2026
  20. “The Centers for Medicare & Medicaid Services (CMS) is extending the Medicare GLP-1 Bridge through December 31, 2027.”
    CMS HPMS memo, April 21, 2026 · as of Oct 17, 2026

Did this page answer your question?